Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 410

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 410
---
 successful, this trial could expand the utility of IFx-2.0beyond advanced Merkel cell carcinoma. IFx-3.0. IFx-3.0is our mRNA innate immune agonist for intravenous or autologous whole cell administration. We believe that advancing an mRNA innate immune agonist candidate for systemic or autologous whole cell administration may allow our company to expand the utility of its innate immune agonist technology to blood-related cancers, which are not amenable to intratumoral administration. The first planned application of IFx-3.0,is to target the CD22 receptor, which is over expressed on a number of B cell cancers like aggressive lymphomas. We plan to test various constructs in vitrobefore advancing to humanized immune competent murine models of aggressive lymphoma planned for 2026. 259

Antibody drug or Peptide conjugates.We are also developing novel immune modulating
bifunctional ADCs and APCs to modulate the tumor microenvironment by reprograming MDSCs’ immune suppressing capabilities through inhibition of the Delta Opioid Receptor on MDSCs while localizing checkpoint inhibitors to checkpoint release
activated T cells in the tissue where the tumor resides. TuHURA is working on developing and expanding a portfolio of novel Delta specific small molecule or peptidomimetic inhibitors of MDSC immunosuppressive functions as potential modulators of the
tumor microenvironment alone or conjugated to an immune effector to construct its bi-functional ADCs. The Company’s prototype APC consists of a proprietary peptidomimetic inhibitor of the Delta Opioid
Receptor conjugated to an antiPD-1 checkpoint inhibitor. Preclinical studies demonstrated that the Company’s APC significantly prolonged survival compared to
antiPD-1 checkpoint inhibitor alone in a murine model of PD-1 resistant lung cancer.

Our History and Team

Legacy
TuHURA’s predecessor company was formed as Morphogenesis, Inc. in 1995 by Drs. Patricia and Michael Lawman. Our IFx technology was developed in the laboratory of Dr. Michael Lawman at the Walt Disney Memorial Cancer Institute, where
Dr. Michael Lawman was formerly a Director of the Institute, and Dr. Patricia Lawman was formerly Division Director of Cancer Molecular Biology at the Institute. Dr. Michael Lawman is a Fellow of the Royal Society of Biology, former
Associate Professor at University of South Florida, and former Scientific Research Director of Pediatric Hematology/Oncology at St.